Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors

Watch this concise interactive module to gain expert perspective on antibody-drug conjugates and their emerging role in the treatment of lung cancer, including mechanism of action, toxicities, and biomarker selection.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 7, 2022 Expired: February 6, 2023

Download this brief slideset on what an antibody-drug conjugate is, along with how they may fit into the current treatment paradigm for lung cancer.

Helena A. Yu, MD Released: February 7, 2022

Watch this concise interactive module to gain expert perspective on the role of HER3 in lung cancer, including its role in oncogenesis and value as a therapeutic target.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 27, 2021 Expired: October 26, 2022

Download this brief slideset on the role of HER3 in lung cancer along with an introduction to the HER3-targeted antibody–drug conjugate patritumab deruxtecan.

Helena A. Yu, MD Released: October 27, 2021

Watch this concise interactive module to gain a better understanding of resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC and an introduction to ways it is being therapeutically addressed.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 19, 2021 Expired: November 18, 2022

Download this brief slideset on resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC and ways it is being therapeutically addressed.

Helena A. Yu, MD Released: November 19, 2021

Watch this concise interactive module to gain a better understanding of treatment options for patients with advanced EGFR-mutated NSCLC whose disease is resistant to first-line EGFR TKI therapy.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 19, 2021 Expired: November 18, 2022

Download this brief slideset on treatment options for patients with advanced EGFR-mutated NSCLC whose disease has progressed on first-line EGFR TKI therapy.

Helena A. Yu, MD Released: November 19, 2021

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.

Elise Hitron, MSN, FNP-C Frank Schneider, MD Conor Ernst Steuer, MD Released: January 26, 2022